Gapping down
News:
- OSMT -26.8% (receives letter from FDA for NDA for arbaclofen; FDA recommends co conduct a new study to show efficacy of arbaclofen)
- CDAK -6.8% (Phase 1 exoIL-12 update)
- MVIS -6.6% (enters into $13 mln At-the-Market equity offering agreement with Craig-Hallum Capital)
- DPW -1.7% (reports Alzamend Neuro's Confidential submission of a draft registration statement relating to the proposed IPO of its common stock)
- VXX -0.9% (softness with US futures trading higher)